|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||11.05 - 11.58|
|52-week range||5.42 - 25.95|
|PE ratio (TTM)||N/A|
|Earnings date||9 Aug 2017 - 14 Aug 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||15.40|
DEVON, Pa., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments, today announced that it will concentrate its focus on rare (meeting the US FDA designation of an orphan disease, affecting fewer than 200,000 people in the U.S.) and near-rare (affecting fewer than one million people in the U.S.) neurological and psychiatric (“neuropsychiatric”) disorders with high unmet medical needs. In 2018, the Company intends to develop ZYN002 in a pivotal Phase 2/3 program in Fragile X syndrome (FXS) and in Phase 2 programs in refractory epilepsies, including adult refractory focal epilepsy and developmental and epileptic encephalopathies (DEE) in pediatric and adolescent patients.
Experts expect a serious cannabis shortage as Canada looks to legalize recreational cannabis in 2018, creating huge opportunities for savvy investors
On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 63 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Microchip Technology, United Continental and Zynerba Pharmaceuticals highlighted as Zacks Bull and Bear of the Day